Side Events – Agenda

Explore Cutting-Edge Precision Medicine Technology

Access below the timetable and agenda of PrecisionMed technology side events

Tuesday 24 May

24 May
10:00 – 10:45

Genetics for Non-geneticists


  • Dr. Cristina Skrypnyk – Assistant Professor, Al-Jawhara Centre
  • Dr. Burhan Fakhurji, Founder and CEO of iGene Medical Training and Molecular Research Center
  • Dr Saba Habibollah, MD, MSc, PhD, Clinical Scientist (Genetics) and Head of Education, Development and Quality Improvement, Iranian Hospital

24 May
11:00 – 11:45

It’s Getting Personal: Tumour Molecular Profiling with Cancer Precision & Co

The German medical genetic diagnostics company CeGaT GmbH developed a comprehensive approach to precisely characterise tumors regardless of their origin. CancerPrecision is a dedicated somatic oncology gene panel that enables personalised approach in tumor diagnostics and provides treating physicians with valuable information to make a decision on a therapeutic strategy to apply.

Speaker: Dmitri Ossipov, PhD, Head of Sales, EMEA – CeGaT GmbH

24 May
12:00 – 12:45

Expanding market entry of our innovations towards laboratory-based testing services

We are looking for investors to expand our operations utilising our own products and optimised services in various regions globally. This can be achieved by setting up satellite laboratories, perform validation studies on our current and pipeline products, validate lab-based testing in various regions and expand our distribution networks.

Speaker: Joseph Curuana, Director Omnigene

24 May
15:00 – 15:45

Omics Approach in Rare Disease and the Challenge of Small Numbers of Patients

Many studies have investigated the role of circulating proteins in COVID-19 disease using different proteomics platforms. In this talk, several studies using Olink technology will be presented, for example, on whether angiopoietin 2 is associated with the induction of vascular necroptosis in COVID-19 acute respiratory distress syndrome or whether there are differences between, for example, bacterial sepsis and COVID-19. In addition, to identify the most robust protein markers for the disease and underlying pathways relevant in different conditions, Olink proteomic profiles from two newly recruited COVID-19 studies were combined with those from three previously published COVID-19 studies. For these studies, three Olink panels (Inflammation and Cardiovascular II & III) were compared with 253 unique proteins. Case/control analysis revealed thirteen proteins (CCL16, CCL7, CXCL10, CCL8, LGALS9, CXCL11, IL1RN, CCL2, CD274, IL6, IL18, MERTK, IFNg, and IL18R1) that were differentially expressed in COVID-19 patients in all five studies. Pathway analysis revealed consistent trends in all studies with pathways related to cytokine-cytokine interaction, IL18 signaling, fluid shear stress, and rheumatoid arthritis.


Dr Frank Schmidt, Associated Professor of Biochemistry and Director of the Proteomics Core of Weill Cornell Medicine in Qatar

Dr Houari Abdesselem, Manager, Proteomics Core Facility, Qatar Biomedical Research Institute, Hamad Bin Khalifa University

Dr Stefan Nierkens, Medical Immunologist, Center for Translational Immunology, University Medical Center Utrecht

Moderator: Raza Ahmed, Olink Proteomics

24 May
15:55 – 16:40

Genetics-based Breast Cancer Personalized Prevention Prgrams in Europe

Current cancer screening programs consider only age as a risk factor, which makes them not – precise and outdated. Our individual cancer risks are very different. Using monogenic pathogenic variant and polygenic risk score testing we can evaluate individual risk levels for common cancers and make with this prevention programs more precise and efficient. Estonia is one of the first countries in the world where genetics – based breast cancer personalized prevention program is implemented and other similar programs are following.

Speaker: Dr. Peeter Padrik, CEO & Founder, Antegenes

24 May
16:45 – 17:30

The Power of Stem Cells

Speaker: Dr. Fatma Alhashimi PhD, Director of Sheikh Zayed Genetic Research Centre

Wednesday 25 May

25 May
09.45 – 10.30


25 May
10.45 – 11.30

Explore how 1-day NGS can help you accelerate your lab

Dr. Jermann obtained his PhD degree in genetics in 2014, uncovering the mechanisms of gene expression regulation through epigenetic processes. He then worked as an expert for next-generation sequencing where he helped establish and support several NGS-based diagnostic laboratories throughout Switzerland and the EMEA region. Since 2017, Dr. Jermann is working at the institute of medical genetics and pathology at the University Hospital in Basel, Switzerland, where he is in charge of the molecular diagnostics and R&D units.

Speaker: Dr Philips Jermann, Chief Molecular Biologist, University Hospital, Basel

25 May
11:35 – 12:20

Breakthrough Cancer screening solution : A new paradigm in early cancer detection

The importance of early diagnosis, through advanced FDA approved cancer screening, specifically the advancements in comparison to more conventional methods.

Speaker: Dr Ramin Ajami, MD, MSC PGDip Oncology UK. President and founder of Lifegen. Honorary Senior Associate specialist at Guy’s and St. Thomas’ Hospital London.

25 May
13:30 – 14:15

Precision Medicine and the Transformation of Health Care in the Middle East

Explore a comprehensive genomic tumour profiling and how this approach is becoming standard of care for biomarker testing and truly enabling precision medicine. An increasing amount of therapies coming to the market from which patients can benefit from across tumour types. With the increase of therapies there is an increasing demand to test for multiple different biomarkers from a limited amount of tissue.

Next generation sequencing is a technology uniquely positioned to be able to address many different biomarkers from a small amount of tissue. Comprehensive genomic profiling of tumours is becoming the standard of care and enables screening across multiple gene >500 genes simultaneously. Comprehensive genomic profiling enables the detection of different variant classes from both DNA and RNA but also more recent complex biomarkers like Tumour mutation burden (TMB), microsatellite instability (MSI) and homologous recombinational deficiency (HRD). Comprehensive genomic profiling enables an hypothesis free approach truly enabling precision medicine.

Speaker: Dr. Samih Alqawlaq, Senior Clinical Sales Specialist, Illumina

25 May
15:20 – 16:05

Immune Precision Medicine in Cancers- Clinical Implications and Updated Scientific Data

Nowadays, precision oncology goes beyond the genomic profile of the tumor. Assessment of the immune response to cancer can provide valuable insight into the microenvironment of the tumor and interaction with the body physiological mechanisms. Patient individual recurrence risk and clinical outcomes highly corelate with the immune response.

Immunoscore® diagnostic technology assesses the patient’s immune response at the tumor site to refine the patient’s risk profile and develop an optimized personalized treatment plan that minimizes exposure to potentially toxic chemotherapy.

Immunoscore® in colon cancer is available as a CLIA or CE marked test to answer to the current context of colorectal cancer which is a major global public health problem with an urgent need to refine diagnosis and treatment.

This robust technology has also potential as a diagnostic tool for many other cancers, as immune response to tumor is a key hallmark of disease progression.

Speaker: Dr Marjane Le Bagousse, Director, Medical & Market Development, Veracyte Immuno-Oncology

25 May
16:15 – 17:00

How Twist Lead the Way in Personalised Medicine

How twist NGS products helps researchers and hospitals to successfully diagnose cancer and move towards a personalised medicine

Speaker: Dr Vishal Dixit, Director, Field Application Scientist, Twist Bioscience